Stephens Investment Management Group LLC Decreases Stake in Insulet Co. (NASDAQ:PODD)

Stephens Investment Management Group LLC trimmed its position in shares of Insulet Co. (NASDAQ:PODD) by 6.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 75,982 shares of the medical instruments supplier’s stock after selling 4,810 shares during the period. Stephens Investment Management Group LLC owned about 0.11% of Insulet worth $19,837,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. Integrated Wealth Concepts LLC increased its position in shares of Insulet by 1.7% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 2,561 shares of the medical instruments supplier’s stock valued at $596,000 after purchasing an additional 42 shares during the last quarter. Nisa Investment Advisors LLC grew its stake in shares of Insulet by 1.0% during the fourth quarter. Nisa Investment Advisors LLC now owns 4,388 shares of the medical instruments supplier’s stock worth $1,146,000 after purchasing an additional 43 shares in the last quarter. Glenmede Trust Co. NA increased its holdings in Insulet by 2.3% in the third quarter. Glenmede Trust Co. NA now owns 2,080 shares of the medical instruments supplier’s stock valued at $484,000 after buying an additional 47 shares during the last quarter. Graypoint LLC raised its stake in Insulet by 5.3% in the fourth quarter. Graypoint LLC now owns 930 shares of the medical instruments supplier’s stock valued at $243,000 after buying an additional 47 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB lifted its holdings in Insulet by 9.6% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 538 shares of the medical instruments supplier’s stock worth $140,000 after buying an additional 47 shares during the last quarter.

Insider Transactions at Insulet

In related news, EVP Eric Benjamin sold 12,394 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the sale, the executive vice president now owns 11,383 shares in the company, valued at $3,187,240. This trade represents a 52.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Lauren Budden sold 915 shares of Insulet stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total value of $252,192.30. Following the completion of the sale, the chief accounting officer now directly owns 5,733 shares in the company, valued at $1,580,129.46. This represents a 13.76 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.47% of the company’s stock.

Insulet Trading Down 1.6 %

Shares of PODD stock opened at $283.08 on Monday. The company has a market capitalization of $19.86 billion, a P/E ratio of 48.47, a price-to-earnings-growth ratio of 3.61 and a beta of 1.23. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The business’s 50 day moving average is $270.27 and its two-hundred day moving average is $241.58. Insulet Co. has a twelve month low of $160.19 and a twelve month high of $289.46.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $0.90 earnings per share for the quarter, beating analysts’ consensus estimates of $0.77 by $0.13. The firm had revenue of $543.90 million for the quarter, compared to analyst estimates of $518.50 million. Insulet had a net margin of 21.22% and a return on equity of 27.98%. During the same period last year, the firm posted $0.71 EPS. Equities analysts forecast that Insulet Co. will post 3.22 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on PODD shares. Morgan Stanley increased their price objective on Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a report on Monday, November 11th. TD Cowen increased their price target on shares of Insulet from $264.00 to $324.00 and gave the company a “buy” rating in a research note on Friday, January 3rd. Sanford C. Bernstein began coverage on shares of Insulet in a research report on Wednesday, November 6th. They set an “outperform” rating and a $300.00 price objective for the company. BTIG Research increased their target price on shares of Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Finally, Barclays boosted their price target on shares of Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a research report on Monday, November 11th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat, Insulet presently has a consensus rating of “Moderate Buy” and an average price target of $277.13.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.